The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type  2 Diabetes: A Cost of Control Analysis in Spain

ConclusionBoth doses of semaglutide were associated with comparable or lower costs of control versus sitagliptin when considering endpoints incorporating hypoglycemia and weight loss alongside glycemic control, and lower costs of control versus dulaglutide 1.5  mg for all endpoints in Spain.Plain Language SummaryPlain language summary available for this article.

Source: Diabetes Therapy - January 9, 2020 Category: Endocrinology Source Type: research